<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Viatris Inc — News on 6ix</title>
<link>https://6ix.com/company/viatris-inc</link>
<description>Latest news and press releases for Viatris Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 10:59:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/viatris-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d5fe78dffbe2df1219fc.webp</url>
<title>Viatris Inc</title>
<link>https://6ix.com/company/viatris-inc</link>
</image>
<item>
<title>Viatris to Report First Quarter 2026 Financial Results on May 7, 2026</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-to-report-first-quarter-2026-financial-results-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-to-report-first-quarter-2026-financial-results-on-may-7-2026</guid>
<pubDate>Mon, 13 Apr 2026 10:59:00 GMT</pubDate>
<description>Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report first quarter 2026 financial results on Thursday, May 7, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.</description>
</item>
<item>
<title>Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-announces-multiple-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-announces-multiple-data-presentations-at-the-2026-american-society-of-cataract-and-refractive-surgery-annual-meeting</guid>
<pubDate>Fri, 10 Apr 2026 10:59:00 GMT</pubDate>
<description>Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that four abstracts will be presented at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in Washington, D.C., April 10-13, 2026.</description>
</item>
<item>
<title>Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-advances-innovative-portfolio-with-approval-of-effexorr-in-japan-for-adults-with-generalized-anxiety-disorder-gad</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-advances-innovative-portfolio-with-approval-of-effexorr-in-japan-for-adults-with-generalized-anxiety-disorder-gad</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Addresses a Significant Unmet Need in Japan as First and Only Approved Treatment Option for GADPITTSBURGH, March 23, 2026 /PRNewswire/ -- Viatris Inc.</description>
</item>
<item>
<title>Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-to-outline-its-vision-for-sustained-revenue-and-earnings-growth-through-2030</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-to-outline-its-vision-for-sustained-revenue-and-earnings-growth-through-2030</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Growing Base Business Evolving Into More Durable Portfolio of Higher-Margin Generics, Value-Added Medicines and Established Brands Expecting Impactful</description>
</item>
<item>
<title>GoodRx Partners with Viatris to Offer Up to 85% Savings on Established Brand Medications</title>
<link>https://6ix.com/company/viatris-inc/news/goodrx-partners-with-viatris-to-offer-up-to-85percent-savings-on-established-brand-medications-2</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/goodrx-partners-with-viatris-to-offer-up-to-85percent-savings-on-established-brand-medications-2</guid>
<pubDate>Wed, 11 Mar 2026 13:00:00 GMT</pubDate>
<description>SANTA MONICA, Calif., March 11, 2026--GoodRx (Nasdaq: GDRX), the leading platform for prescription savings in the U.S., today announced a new collaboration with Viatris, a global healthcare company, to make 17 of its established brand medications more affordable for consumers. Beginning today, eligible commercially insured patients may pay as low as $0–$4 on select Viatris medications through GoodRx. Cash-paying consumers, regardless of insurance status, can use GoodRx to access discounted cash</description>
</item>
<item>
<title>Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-reports-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-reports-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Reports Fourth-Quarter Total Revenues of $3.7B and Full-Year 2025 Total Revenues of $14.3BMeets or Exceeds 2025 Financial Guidance Across All Key</description>
</item>
<item>
<title>Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-maintains-dividend-policy-for-2026-and-announces-quarterly-dividend</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-maintains-dividend-policy-for-2026-and-announces-quarterly-dividend</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026</description>
</item>
<item>
<title>FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia</title>
<link>https://6ix.com/company/viatris-inc/news/fda-accepts-viatris-supplemental-new-drug-application-for-mr-141-phentolamine-ophthalmic-solution-075percent-for-the-treatment-of-presbyopia</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/fda-accepts-viatris-supplemental-new-drug-application-for-mr-141-phentolamine-ophthalmic-solution-075percent-for-the-treatment-of-presbyopia</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>FDA PDUFA Goal Date Set for October 17, 2026PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today</description>
</item>
<item>
<title>Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-report-fourth-quarter-full-213000773</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-report-fourth-quarter-full-213000773</guid>
<pubDate>Tue, 03 Feb 2026 21:30:00 GMT</pubDate>
<description>Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 26, 2026. Company executives will host a webcast at 8:30 a.m. ET on the same date to discuss the results.</description>
</item>
<item>
<title>Viatris Appoints Matthew J. Maletta as Chief Legal Officer</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-appoints-matthew-j-maletta-133000269</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-appoints-matthew-j-maletta-133000269</guid>
<pubDate>Tue, 03 Feb 2026 13:30:00 GMT</pubDate>
<description>Viatris Inc. (Nasdaq: VTRS) announced today that Matthew J. Maletta has been appointed Chief Legal Officer (CLO), effective February 9, 2026. The appointment follows the transition of the Company's current CLO, Brian Roman, after more than 20 years of exemplary service to Viatris and its predecessor company, Mylan. Roman, who has served in multiple leadership positions and played a key role in supporting the Company's operations, portfolio and growth initiatives, will stay on through April 1, 20</description>
</item>
<item>
<title>Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-expands-innovative-portfolio-cardiovascular-diseases-companys-first-launch</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-expands-innovative-portfolio-cardiovascular-diseases-companys-first-launch</guid>
<pubDate>Tue, 20 Jan 2026 05:00:00 GMT</pubDate>
<description>Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq:</description>
</item>
<item>
<title>Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-appoints-lara-ramsburg-chief-140500750</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-appoints-lara-ramsburg-chief-140500750</guid>
<pubDate>Thu, 08 Jan 2026 14:05:00 GMT</pubDate>
<description>Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing transformation efforts, this newly combined role is designed to continue to advance the company's culture and connectivity across the globe, while also strengthening the alignment of the organization's internal and external stakeholder communication strategies.</description>
</item>
<item>
<title>Viatris Provides Pipeline Update on Four Regulatory Milestones</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-provides-pipeline-update-four-regulatory-milestones-2025-12-18</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-provides-pipeline-update-four-regulatory-milestones-2025-12-18</guid>
<pubDate>Thu, 18 Dec 2025 05:00:00 GMT</pubDate>
<description>Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension)U.S. FDA</description>
</item>
<item>
<title>Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-present-44th-annual-jp-morgan-healthcare-conference-2025-12-17</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>PITTSBURGH, Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th</description>
</item>
<item>
<title>Viatris Recognized as 2025 Best Workplaces™ in Ontario and for Giving Back</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-recognized-2025-best-workplaces-140000119</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-recognized-2025-best-workplaces-140000119</guid>
<pubDate>Mon, 15 Dec 2025 14:00:00 GMT</pubDate>
<description>Viatris Inc. (Nasdaq: VTRS) has been named one of the 2025 Best Workplaces™ in Ontario and one of the 2025 Best Workplaces™ for Giving Back in Canada. These recognitions highlight Viatris in Canada's commitment to fostering a culture where colleagues are enthusiastic about the work they do, feel valued, engaged and motivated. It is also important to Viatris that we seek out meaningful opportunities to give back.</description>
</item>
<item>
<title>Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-announces-agreement-monetize-its-equity-stake-biocon-biologics-limited-2025</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-announces-agreement-monetize-its-equity-stake-biocon-biologics-limited-2025</guid>
<pubDate>Sat, 06 Dec 2025 05:00:00 GMT</pubDate>
<description>Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon LimitedTransaction Accelerates the Expiration of Biosimilars Non-Compete</description>
</item>
<item>
<title>Viatris to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-participate-upcoming-investor-conferences-2025-11-24</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-participate-upcoming-investor-conferences-2025-11-24</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>PITTSBURGH, Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two</description>
</item>
<item>
<title>Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-recognized-one-fortune-worlds-best-workplacestm-2025-2025-11-13</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-recognized-one-fortune-worlds-best-workplacestm-2025-2025-11-13</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>PITTSBURGH, Nov. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best</description>
</item>
<item>
<title>Viatris Reports Third Quarter 2025 Results and Updates 2025 Financial Guidance</title>
<link>https://6ix.com/company/viatris-inc/news/viatris-reports-third-quarter-2025-results-and-updates-2025-financial-guidance-2025</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/viatris-reports-third-quarter-2025-results-and-updates-2025-financial-guidance-2025</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Delivers Total Revenues in Line With Expectations, Reflecting Strong Execution of its Global Business Makes Late-Stage Pipeline Progress Including NDA</description>
</item>
<item>
<title>Policy Engagement to Break Down Barriers to Access and Build Resilient Health Systems at Viatris</title>
<link>https://6ix.com/company/viatris-inc/news/policy-engagement-break-down-barriers-153000009</link>
<guid isPermaLink="true">https://6ix.com/company/viatris-inc/news/policy-engagement-break-down-barriers-153000009</guid>
<pubDate>Tue, 04 Nov 2025 15:30:00 GMT</pubDate>
<description>NORTHAMPTON, MA / ACCESS Newswire / November 4, 2025 / Public policies are central factors in determining healthcare interventions and access to medicines and treatment. Viatris leverages our global experiences, scientific expertise and operations ...</description>
</item>
</channel>
</rss>